Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein

Cancer Biology and Therapy

Volumn 10, Issue 5, 2010, Pages 483-491

  Yin, Li ^a   Ahmad, Rehan ^a   Kosugi, Michio ^a   Kawano, Takeshi ^a   Avigan, David ^a   Stone, Richard ^a   Kharbanda, Surender ^a   Kufe, Donald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bcr Abl; CML; MUC1; Myeloid differentiation; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CD11B ANTIGEN; CD14 ANTIGEN; GLYCOPROTEIN P 15095; GO 201; MUCIN 1; MUCIN 1 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER REGRESSION; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; MOLECULARLY TARGETED THERAPY; MOUSE; NECROSIS; NONHUMAN; OLIGOMERIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD11; ANTIGENS, CD11B; ANTIGENS, CD11C; ANTIGENS, CD14; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOBLOTTING; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; MUCIN-1; MYELOPOIESIS; PEPTIDES; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT;

EID: 77957152778     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.5.12584     Document Type: Article

References (30)

1. Nowell PC. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132:1497.
2. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290-3.
3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6. (Pubitemid 126664202)
4. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112:4808-17.
5. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80.
6. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7:441-53.
7. Savona M, Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008; 8:341-50. (Pubitemid 351589698)
8. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML N. Engl J Med 2004; 351:657-67.
9. Minami Y, Stuart SA, Ikawa T, Jiang Y, Banno A, Hunton IC, et al. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci USA 2008; 105:17967-72.
10. Kawano T, Ito M, Raina D, Wu Z, Rosenblatt J, Avigan D, et al. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res 2007; 67:11576-84.
11. Kufe D. Mucins in cancer: function, prognosis and therapy. Nature Reviews Cancer 2009; 9:874-85.
12. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3:223-32. (Pubitemid 15184701)
13. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 2007; 27:992-1004.
14. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks GSK3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 2005; 65:10413-22.
15. Yamamoto M, Bharti A, Li Y, Kufe D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and β-catenin in cell adhesion. J Biol Chem 1997; 272:12492-4. (Pubitemid 27203339)
16. Li Y, Bharti A, Chen D, Gong J, Kufe D. Interaction of glycogen synthase kinase 3β with the DF3/MUC1 carcinoma-associated antigen and β-catenin. Mol Cell Biol 1998; 18:7216-24.
17. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S, Kufe D. MUC1 oncoprotein activates the IκB kinase β complex and constitutive NFκB signaling. Nat Cell Biol 2007; 9:1419-27.
18. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S, Kufe D. MUC1-C oncoprotein functions as a direct activator of the NFkappaB p65 transcription factor. Cancer Res 2009; 69:7013-21.
19. Raina D, Ahmad R, Kumar S, Ren J, Yoshida K, Kharbanda S, Kufe D. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J 2006; 25:3774-83. (Pubitemid 44300263)
20. Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M, Kufe D. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Bio Chem 2007; 282:19321-30.
21. Raina D, Ahmad R, Joshi M, Yin L, Wu Z, Kawano T, et al. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009; 69:5133-41.
22. Joshi MD, Ahmad R, Raina D, Rajabi H, Bubley G, Kharbanda S, Kufe D. MUC1 oncoprotein is a drug-gable target in human prostate cancer cells. Mol Cancer Ther 2009; 8:3056-65.
23. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100:3041-4.
24. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005; 65:10536-44.
25. Ren J, Bharti A, Raina D, Chen W, Ahmad R, Kufe D. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene 2006; 25:20-31. (Pubitemid 43050000)
26. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, et al. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008; 22:1191-9. (Pubitemid 351833787)
27. Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, et al. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 2000; 96:2284-91.
28. Alitalo R. Induced differentiation of K562 leukemia cells: a model for studies of gene expression in early megakaryoblasts. Leuk Res 1990; 14:501-14.
29. Luisi-DeLuca C, Mitchell T, Spriggs D, Kufe D. Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosyl cytosine. J Clin Invest 1984; 74:821-7. (Pubitemid 14031017)
30. Yin L, Ahmad R, Kosugi M, Kufe T, Vasir B, Avigan D, et al. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharm 2010; In press.